Phase 2/3 trial will enroll approximately 4,000 healthy pregnant women in the U.S., Canada, Argentina, Brazil, Chile, Mozambique, South Africa, U.K., and Spain First participants dosed in the U.S. Women enrolled in the trial will be unblinded shortly after giving birth to allow those women who originally received placebo to be vaccinated while staying in the study
EMBLAVEO® is the first β-lactam/β-lactamase inhibitor antibiotic combination approved in the European Union for treating serious infections in adult patients caused by multidrug-resistant Gram-negative bacteria,…
ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk. The vaccine was well-tolerated…
NEW YORK, March 22, 2024 – Pfizer Inc. (NYSE: PFE) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European…
PREVENAR 20® (20-valent Pneumococcal Conjugate Vaccine) offers the broadest serotype coverage of any pediatric pneumococcal conjugate vaccine to help protect infants and children from the…
ECHELON-3 trial of ADCETRIS in combination with lenalidomide and rituximab showed significant improvement in primary endpoint of overall survival and in secondary endpoints of progression…
VELSIPITY is the first and only oral advanced ulcerative colitis therapy approved for use in patients 16 years of age or older in the EU…
Black fathers are often portrayed as absent or distant, but that isn’t what most people experience, according to both data and Black dads themselves. Such…
The CDC recommends getting new shots for protection against multiple COVID variants. Adults who got the updated shots were 54% less likely to get infected.
– Pivotal trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall and progression-free survival – – If approved, PADCEV with KEYTRUDA would be…
This week, from January 25-27th, Pfizer will join the genitourinary oncology community at the 20th annual meeting of the American Society of Clinical Oncology Genitourinary…
